SpliSense is an Israel-based company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis and pulmonary diseases.
Our innovative approach targets unmet needs in pulmonary diseases. SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and restore protein function.
SpliSense technology is based on the research of Prof. Batsheva Kerem (Hebrew University), which illustrated the value of ASO-based medication for genetic diseases. The company’s leadership has a strong track record in the genetics of pulmonary diseases, development of ASO therapies and inhaled treatments.
Our platform can be used for treatment of a variety of diseases, and our pipeline includes innovative therapies in various stages, from discovery to IND phase. Furthermore, SpliSense has robust, diverse IP protecting its technologies and programs.